ABSTRACT
Objective To discuss the treatment effect of ginseng polysaccharide injection auxiliary GP chemotherapy for patients with non-small cell lung cancer.Methods 130 cases of patients with non-small cell lung cancer from June 2011 to June 2013 were randomly divided into two groups, 65 cases in each group.The control group was given gemcitabine and cisplatin treatment.The observation group were treated with ginseng polysaccharide injection on the basis of the control group.After 3 months of continuous therapy, the therapeutic effect, T-lymphocyte subsets, adverse events, quality of life scores of the two groups were compared, and survival in two groups of patients were also compared after 1 year follow-up.Results The total efficiency and clinical benefit rate in observation group were 58.5%, significantly better than the control group ( 41.5%) , the difference was statistically significant (χ2 =3.72, P<0.05);CD3, CD4 and CD4 /CD8 in observation group were significantly higher than the control group, the differences were statistically significant (t =5.735, 7.885, 7.326, P<0.05), whereas CD8 was significantly lower than the control group, the difference was statistically significant (t=2.442, P<0.05).The main adverse reactions of the two groups of patients during treatment were myelosuppression (WBC and platelet decreasing and anemia ) and gastrointestinal reaction.Score of life quality in observation group was ( 71.5 ±12.9 ) after treatment, significantly higher than the control group (64.2 ±12.2), the difference was statistically significant (t=3.315, P<0.05).1-year survival rate in the observation group were 63.1%, and 52.3% in the control group.Conclusion Ginseng Polysaccharide injection auxiliary GP chemotherapy for non-small cell lung cancer has significantly efficacy, enhances immunity, reduces side effects, better quality of life.
ABSTRACT
Objective To investigate clinical efficacy of additive LiuJunZi decoction in treatment of patients with chronic obstructive pneumonia ( COPD) of both lung and spleen deficiency in stable phase.Methods A total of 58 patients with deficiency of both lung and spleen type stable COPD patients were randomly divided into treatment group and control group by a random number table, 29 cases in each group, patients in two groups were treated with salmeterol and fluticasone propionate powder for inhalation.On this basis, the treatment group were given additive Liujunzi Decoction, orally, with 3 months treatment.The clinical signs and symptoms of patients, pulmonary function, index of sputumand acute attack proportion in a year were observed and compared.Results After different treatment, total efficiency was 93.1% in treatment group, which was obviously higher than 65.5%in control group (P<0.05).After treatment, the values of FEV1 and FEV1/FVC improved compared with before treatment, and the above indexes of treatment group significantly improved compared with control group (P<0.05).The HDACs activety, levels of TNF-αand IL-8 mproved compared with before treatment, and the above indexes of treatment group significantly improved compared with control group (P<0.05).The acute attack was two cases in treatment group(6.9%), seven cases in control group(24.1%), but the difference had no statistically significant.Conclusion The additive Liujunzi decoction in the treatment of both lung and spleen deficiency type chronic obstructive pulmonary disease ( COPD) in stable phase has exact clinical curative effect, can significantly improve clinical symptoms and laboratory indexes, control the progression of the disease, and improve life quality of the patients.